Literature DB >> 30054151

Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study.

Jeffrey J Bazarian1, Peter Biberthaler2, Robert D Welch3, Lawrence M Lewis4, Pal Barzo5, Viktoria Bogner-Flatz6, P Gunnar Brolinson7, Andras Büki8, James Y Chen9, Robert H Christenson10, Dallas Hack11, J Stephen Huff12, Sandeep Johar13, J Dedrick Jordan14, Bernd A Leidel15, Tobias Lindner15, Elizabeth Ludington16, David O Okonkwo17, Joseph Ornato18, W Frank Peacock19, Kara Schmidt20, Joseph A Tyndall21, Arastoo Vossough22, Andy S Jagoda23.   

Abstract

BACKGROUND: More than 50 million people worldwide sustain a traumatic brain injury (TBI) annually. Detection of intracranial injuries relies on head CT, which is overused and resource intensive. Blood-based brain biomarkers hold the potential to predict absence of intracranial injury and thus reduce unnecessary head CT scanning. We sought to validate a test combining ubiquitin C-terminal hydrolase-L1 (UCH-L1) and glial fibrillary acidic protein (GFAP), at predetermined cutoff values, to predict traumatic intracranial injuries on head CT scan acutely after TBI.
METHODS: This prospective, multicentre observational trial included adults (≥18 years) presenting to participating emergency departments with suspected, non-penetrating TBI and a Glasgow Coma Scale score of 9-15. Patients were eligible if they had undergone head CT as part of standard emergency care and blood collection within 12 h of injury. UCH-L1 and GFAP were measured in serum and analysed using prespecified cutoff values of 327 pg/mL and 22 pg/mL, respectively. UCH-L1 and GFAP assay results were combined into a single test result that was compared with head CT results. The primary study outcomes were the sensitivity and the negative predictive value (NPV) of the test result for the detection of traumatic intracranial injury on head CT.
FINDINGS: Between Dec 6, 2012, and March 20, 2014, 1977 patients were recruited, of whom 1959 had analysable data. 125 (6%) patients had CT-detected intracranial injuries and eight (<1%) had neurosurgically manageable injuries. 1288 (66%) patients had a positive UCH-L1 and GFAP test result and 671 (34%) had a negative test result. For detection of intracranial injury, the test had a sensitivity of 0·976 (95% CI 0·931-0·995) and an NPV of 0·996 (0·987-0·999). In three (<1%) of 1959 patients, the CT scan was positive when the test was negative.
INTERPRETATION: These results show the high sensitivity and NPV of the UCH-L1 and GFAP test. This supports its potential clinical role for ruling out the need for a CT scan among patients with TBI presenting at emergency departments in whom a head CT is felt to be clinically indicated. Future studies to determine the value added by this biomarker test to head CT clinical decision rules could be warranted. FUNDING: Banyan Biomarkers and US Army Medical Research and Materiel Command.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30054151     DOI: 10.1016/S1474-4422(18)30231-X

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  94 in total

1.  Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury.

Authors:  Elliot J Glotfelty; Thomas Delgado; Luis B Tovar-Y-Romo; Yu Luo; Barry Hoffer; Lars Olson; Tobias Karlsson; Mark P Mattson; Brandon Harvey; David Tweedie; Yazhou Li; Nigel H Greig
Journal:  ACS Pharmacol Transl Sci       Date:  2019-02-11

2.  Correlation of Blood Biomarkers and Biomarker Panels with Traumatic Findings on Computed Tomography after Traumatic Brain Injury.

Authors:  Jussi P Posti; Riikka S K Takala; Linnéa Lagerstedt; Alex M Dickens; Iftakher Hossain; Mehrbod Mohammadian; Henna Ala-Seppälä; Janek Frantzén; Mark van Gils; Peter J Hutchinson; Ari J Katila; Henna-Riikka Maanpää; David K Menon; Virginia F Newcombe; Jussi Tallus; Kevin Hrusovsky; David H Wilson; Jessica Gill; Jean-Charles Sanchez; Olli Tenovuo; Henrik Zetterberg; Kaj Blennow
Journal:  J Neurotrauma       Date:  2019-04-05       Impact factor: 5.269

3.  Point-of-Care Platform Blood Biomarker Testing of Glial Fibrillary Acidic Protein versus S100 Calcium-Binding Protein B for Prediction of Traumatic Brain Injuries: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study.

Authors:  David O Okonkwo; Ross C Puffer; Ava M Puccio; Esther L Yuh; John K Yue; Ramon Diaz-Arrastia; Frederick K Korley; Kevin K W Wang; Xiaoying Sun; Sabrina R Taylor; Pratik Mukherjee; Amy J Markowitz; Sonia Jain; Geoffrey T Manley
Journal:  J Neurotrauma       Date:  2020-09-14       Impact factor: 5.269

4.  An Activity-Based Nanosensor for Traumatic Brain Injury.

Authors:  Julia A Kudryashev; Lauren E Waggoner; Hope T Leng; Nicholas H Mininni; Ester J Kwon
Journal:  ACS Sens       Date:  2020-03-10       Impact factor: 7.711

5.  Pharmacological Optimization for Successful Traumatic Brain Injury Drug Development.

Authors:  Samuel M Poloyac; Richard J Bertz; Lee A McDermott; Punit Marathe
Journal:  J Neurotrauma       Date:  2019-04-10       Impact factor: 5.269

6.  Neurofilament Light Chain-It Is Not Just About Concussions.

Authors:  Jessica M Jarvis; Ericka L Fink
Journal:  Pediatr Crit Care Med       Date:  2020-07       Impact factor: 3.624

Review 7.  Neurochemical biomarkers in spinal cord injury.

Authors:  Brian K Kwon; Ona Bloom; Ina-Beate Wanner; Armin Curt; Jan M Schwab; James Fawcett; Kevin K Wang
Journal:  Spinal Cord       Date:  2019-07-04       Impact factor: 2.772

Review 8.  Neuroimaging of traumatic brain injury in military personnel: An overview.

Authors:  Avnish Bhattrai; Andrei Irimia; John Darrell Van Horn
Journal:  J Clin Neurosci       Date:  2019-07-19       Impact factor: 1.961

9.  Large-scale informatic analysis to algorithmically identify blood biomarkers of neurological damage.

Authors:  Grant C O'Connell; Megan L Alder; Christine G Smothers; Julia H C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-06       Impact factor: 11.205

10.  Identification of Novel Targets of RBM5 in the Healthy and Injured Brain.

Authors:  Travis C Jackson; Keri Janesko-Feldman; Kiersten Gorse; Vincent A Vagni; Edwin K Jackson; Patrick M Kochanek
Journal:  Neuroscience       Date:  2020-04-24       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.